MedTech

We are a Canadian physician & dentist exclusive angel investment group that advises, connects, and invests in disruptive healthcare ventures.

1. Incorporated in Canada
2. Product is clinically relevant and prototype- or MVP-ready
3. You are:
a. Seeking pre-seed, seed, or intermediate financing
b. Open to investments from non-syndicated, individual physician/dentist members with
minimum cheque sizes of $25,000
c. Valued at =< $20M CAD pre-money
4. You have a lead investor and/or have secured at least 50% of the total raise

MedTech

The Hyatt Family Office is an entrepreneur founded private family office with a strong interest in technology.

1. transformational improvements in either dialysis or transplantation, including for example:
a) drugs or other ways to reduce rejection risk (including any potential direct or indirect ways to increase the e-GFR rate);
b) facilitating transplants (e.g. by increasing the supply, either from synthetic kidneys, kidneys created via stem cells, pig kidney transplants), so that lack of organ donations at the right time is not an issue
c) anything in gene editing (through CRISPR or other technologies) for genetic manipulation to remediate kidney decline (just as gene editing is occurring to resolve muscular dystrophy)
2. pessaries
3. improvements to metal pins and plates, or a replacement (such as bone tape) as a way to join bone fragments

MedTech

iGan Partners invests in breakthrough healthcare technologies—primarily medical devices, diagnostics, and AI-enabled healthcare infrastructure—that improve clinical outcomes while reducing the cost of care. The firm focuses on companies at the intersection of clinically validated innovation and scalable commercialization, partnering early with founders to support regulatory strategy, clinical adoption, and strategic exits to global healthcare leaders.

We are not looking for biotech or pharma companies.

Digital Health

Investments & Advisory Services

Digital Health

MedTech

INOVAIT is Canada’s image-guided therapy (IGT) and artificial intelligence (AI) network. As a pan-Canadian network, INOVAIT supports companies and academic institutions from coast to coast to commercialize cutting-edge medical technologies that positively impact the healthcare system and create high-quality jobs. The network brings together companies, research institutes, post-secondary institutions, and not-for-profit organizations to collaborate on game-changing projects to transform healthcare. INOVAIT strengthens the Canadian medtech ecosystem by fuelling continuous innovation that revolutionizes healthcare. INOVAIT was established in 2020 by Sunnybrook Research Institute and supported by the Government of Canada’s Strategic Response Fund.

- image-guided therapy
- medical imaging
- artificial intelligence
- machine learning
- big data applications

Pharma

Developing Dual use Biodefence technology

co-development, Licensing to Global

Biotech

J.P. Morgan focus on solutions for life sciences companies at all stages—from startups to established businesses, pre-clinical through commercialization. We have decades of experience in the sector and understand the complex financial and regulatory challenges life sciences companies face. We bring a wealth of expertise and insights to the venture capital space, and we’re ready to help you stay positioned for innovation and growth.

Biotech, medtech, specialty pharma, CRO, CDMO, generics, diagnostics

MedTech

Leva Capital is an early-stage venture fund investing in MedTech and Digital Health companies that improve patient outcomes, expand access to care, and support human longevity. We back capital-efficient teams with a clear path to regulatory approval and commercialization, often leveraging Canada's talent base and innovation ecosystem to scale globally. Through Fund I, Leva has invested in 22 early-stage companies, primarily at the seed stage, with 18 based in Canada. We are currently raising Fund II and plan to continue supporting the Canadian ecosystem.

Pre-seed to series A-stage Medtech, Digital Health, Biotech, Diagnostics companies.

Biotech

Linearis with its tandem Ventures Fund and Laboratory, is pioneering and supporting discoveries to prevent, detect, and cure diseases through direct investments in innovative AI-powered life sciences companies (Seed to Series B).

AI-powered life sciences companies (BioPharma, MedTech, Diagnostics, Digital Health)
Stage: Seed to Series B

Other

Life sciences venture capital firm

Biotech or medtech companies

MedTech

MEDTEQ+ is an early-stage (pre-seed, seed) hands-on medtech and healthtech investor. We invest in companies we can derisk through our dilutive financing, clinical and commercial networks and/or non-dilutive funding fostering key collaborations. We value strong clinico-economic evidence data or at least a clear understanding of the path leading to generating them.

Team balanced between technical, clinical and commercial expertise, with execution capability and feedback expectations. Prototype demonstrating a differentiated technology that will bring a robust competitive advantage in profitable markets. Clinical need clearly validated by experts, with realistic identification of payers and understanding of integration into or disruption of care trajectories. International ambition on day 1.

Biotech

MPM BioImpact combines the 30+ year track record of the MPM CAPITAL® services and offerings in biotech venture capital with BioImpact’s dedication to impact and 10+ years of experience in public investing. Together, we manage over $3 billion AUM across early-stage venture funds, private/public impact funds and a public equities fund.

Not sure yet

Other

Life science venture development and investment company

Life science companies

Other

Founded in 2009, OBIO® is a not-for-profit, membership-based organization offering programming and infrastructure to support early-stage and venture-backed companies across the therapeutics, medtech, diagnostics, digital health and consumer health sectors. We enable them to raise capital, hire and train industry-ready talent, facilitate the commercialization and adoption of their technologies in health systems, and access infrastructure across various areas of focus: Capital Access & Adoption, Skills Development & Training, Women in Health and Critical Technologies. Through the OBIO® membership, we offer companies and their teams access to mentorship & expert resources, grants, experiential learning opportunities and more.

seed-series A+ stage biotech and medtech startups

Biotech

Omnium Global is a venture studio that supports life sciences companies with fundraising, commercial strategy, and operational execution. We take hands-on leadership in our portfolio companies, turning strong science into partnerable assets. Rather than acting as a traditional investor, Omnium partners closely with founders by deploying not only capital, but also leadership and operational expertise to transform early-stage scientific ideas into fundable, scalable ventures. Through our extensive global network of industry leaders, investors, and technical experts, we unlock opportunities, accelerate development, and optimize outcomes for every venture we support.

Drug delivery platforms, vaccines and infectious disease technologies, AI-enabled biotech tools, advanced biomanufacturing systems, and low-cost biologics aimed at improving global access

MedTech

One Six 8 Ventures is an operator-led venture capital fund targeting early-stage MedTech opportunities with significant global potential. We leverage deep operational expertise to scale nextgen medical innovations toward successful strategic exits.

Seed to Series A
Medtech: in particular in AI Medtech, Surgical Tools, Surgical Robotics, Remote Patient Monitoring

Life Science Tools / Research Tech

OCI helps Ontario innovators get connected with researchers, industry partners, and funding needed to commercialize the next generation of made-in-Ontario IP and solutions.

Ontario-based, minimum 2 FTE, generating revenue, and incorporated for a minimum of 2 years

Pharma

Ontario Centre of Innovation (OCI) is a provincially funded organization that accelerates the commercialization of Ontario-based technologies by connecting industry, academia, investors, and government. OCI supports high-growth companies through targeted funding programs, public–private co-investment, and strategic advisory services across sectors including artificial intelligence, life sciences, advanced manufacturing, mobility, and clean technology. Its mandate is to drive innovation adoption, scale Ontario companies globally, and strengthen the province’s economic competitiveness.

We need ontario based companies only

Biotech

OrbiMed seeks to invest globally in world-class healthcare companies to help drive innovation, address unmet medical needs, and improve patient outcomes.

therapeutics, medical devices